Effects of CPAP in Severe Therapy-resistant Asthma (CPAP-STRA)
Asthma
About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Continuous positive airway pressure, Oxygen consumption
Eligibility Criteria
Inclusion Criteria:
- Individuals with a clinical diagnosis of severe therapy-resistant asthma (STRA), of both sexes, aged between 6 and 18 years, who are under regular follow-up in the asthma outpatient clinic at São Lucas Hospital, PUCRS.
The criteria for the classification of STRA is based on the Global Initiative for Asthma (GINA) guidelines:
- Asthma requiring treatment in steps 4-5 of GINA (≥800 mg/day of budesonide or equivalent, associated with long-acting ß2-adrenergic agonist (LABA);
- Use of continuous oral corticoid or omalizumab, presenting uncontrolled disease;
- Uncontrolled disease characterized by: 1) persistent symptoms or asthma control test (ACT) <20 (> 3 months); 2) acute exacerbations (with intensive care unit admission, at least 2 hospitalizations, or 2 courses of oral corticoid over the last 12 months); Or 3) non-reversible obstruction of pulmonary function, even after corticoid use.
Exclusion Criteria:
- Subjects with cognitive/motor limitations or other chronic diseases (neurological diseases, cardiac anomalies, congenital or immunodeficiencies), which may compromise the evaluation of asthma, as well as the procedures proposed by the present study.
Sites / Locations
- Pontifífia Universidade Católica do Rio Grande do Sul
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Continuous Positive Airway Pressure (CPAP)
CONTROL
Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.